☰

Sivan Sapoznik, Ph.D. - Publications

Affiliations: 
2007 MGV Molecular Genetics Weizmann Institute of Science, Rehovot, Israel 
Area:
Genetics, Molecular Biology, Neuroscience Biology
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

6/11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2010 Shmueli A, Segal M, Sapir T, Tsutsumi R, Noritake J, Bar A, Sapoznik S, Fukata Y, Orr I, Fukata M, Reiner O. Ndel1 palmitoylation: a new mean to regulate cytoplasmic dynein activity. The Embo Journal. 29: 107-19. PMID 19927128 DOI: 10.1038/Emboj.2009.325  0.686
2008 Sapir T, Sapoznik S, Levy T, Finkelshtein D, Shmueli A, Timm T, Mandelkow EM, Reiner O. Accurate balance of the polarity kinase MARK2/Par-1 is required for proper cortical neuronal migration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 5710-20. PMID 18509032 DOI: 10.1523/Jneurosci.0911-08.2008  0.74
2006 Reiner O, Sapoznik S, Sapir T. Lissencephaly 1 linking to multiple diseases: mental retardation, neurodegeneration, schizophrenia, male sterility, and more. Neuromolecular Medicine. 8: 547-65. PMID 17028375 DOI: 10.1385/Nmm:8:4:547  0.634
2006 Shmueli A, Gdalyahu A, Sapoznik S, Sapir T, Tsukada M, Reiner O. Site-specific dephosphorylation of doublecortin (DCX) by protein phosphatase 1 (PP1). Molecular and Cellular Neurosciences. 32: 15-26. PMID 16530423 DOI: 10.1016/J.Mcn.2006.01.014  0.648
2004 Reiner O, Gdalyahu A, Ghosh I, Levy T, Sapoznik S, Nir R, Sapir T. DCX's phosphorylation by not just another kinase (JNK). Cell Cycle (Georgetown, Tex.). 3: 747-51. PMID 15118415 DOI: 10.4161/Cc.3.6.909  0.653
2004 Gdalyahu A, Ghosh I, Levy T, Sapir T, Sapoznik S, Fishler Y, Azoulai D, Reiner O. DCX, a new mediator of the JNK pathway. The Embo Journal. 23: 823-32. PMID 14765123 DOI: 10.1038/Sj.Emboj.7600079  0.662
Low-probability matches (unlikely to be authored by this person)
2014 Ortenberg R, Galore-Haskel G, Greenberg I, Zamlin B, Sapoznik S, Greenberg E, Barshack I, Avivi C, Feiler Y, Zan-Bar I, Besser MJ, Azizi E, Eitan F, Schachter J, Markel G. CEACAM1 promotes melanoma cell growth through Sox-2. Neoplasia (New York, N.Y.). 16: 451-60. PMID 24931667 DOI: 10.1016/j.neo.2014.05.003  0.166
2012 Ortenberg R, Sapir Y, Raz L, Hershkovitz L, Ben Arav A, Sapoznik S, Barshack I, Avivi C, Berkun Y, Besser MJ, Ben-Moshe T, Schachter J, Markel G. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Molecular Cancer Therapeutics. 11: 1300-10. PMID 22466331 DOI: 10.1158/1535-7163.MCT-11-0526  0.103
2010 Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser MJ, Bar J, Shapira R, Kubi A, Nardini G, Tessone A, Treves AJ, Winkler E, Orenstein A, Schachter J. Systemic dysregulation of CEACAM1 in melanoma patients. Cancer Immunology, Immunotherapy : Cii. 59: 215-30. PMID 19633846 DOI: 10.1007/s00262-009-0740-5  0.095
2012 Sapoznik S, Ortenberg R, Galore-Haskel G, Kozlovski S, Levy D, Avivi C, Barshack I, Cohen CJ, Besser MJ, Schachter J, Markel G. CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunology, Immunotherapy : Cii. 61: 1833-47. PMID 22441657 DOI: 10.1007/s00262-012-1245-1  0.057
2012 Sapoznik S, Hammer O, Ortenberg R, Besser MJ, Ben-Moshe T, Schachter J, Markel G. Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clinical & Developmental Immunology. 2012: 818214. PMID 22778766 DOI: 10.1155/2012/818214  0.027
Hide low-probability matches.